Page last updated: 2024-09-05

erlotinib and 2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide

erlotinib has been researched along with 2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide in 1 studies

Compound Research Comparison

Studies (erlotinib)	Trials (erlotinib)	Recent Studies (post-2010) (erlotinib)	Studies (2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide)	Trials (2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide)	Recent Studies (post-2010) (2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide)
221	0	180	17	0	3

Protein Interaction Comparison

Protein	Taxonomy	2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide (IC50)
Tyrosine-protein kinase ABL1	Homo sapiens (human)	2.82
Macrophage colony-stimulating factor 1 receptor	Homo sapiens (human)	0.38
Platelet-derived growth factor receptor beta	Homo sapiens (human)	0.64
Mast/stem cell growth factor receptor Kit	Homo sapiens (human)	0.236
Vascular endothelial growth factor receptor 1	Homo sapiens (human)	0.1365
Vascular endothelial growth factor receptor 3	Homo sapiens (human)	0.018
Vascular endothelial growth factor receptor 2	Homo sapiens (human)	0.0506

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ban, HS; Hirokawa, T; Kawada, J; Nakamura, H; Usui, T	1

Other Studies

1 other study(ies) available for erlotinib and 2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide

Article	Year
Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening. Bioorganic & medicinal chemistry letters, 2008, Jan-01, Volume: 18, Issue:1 Topics: Binding Sites; Cell Line, Tumor; Combinatorial Chemistry Techniques; Crystallography, X-Ray; Drug Design; ErbB Receptors; Humans; Kinetics; Models, Molecular; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship; Substrate Specificity; Vascular Endothelial Growth Factor Receptor-2	2008

Article

Year

Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.

Bioorganic & medicinal chemistry letters, 2008, Jan-01, Volume: 18, Issue:1

Topics: Binding Sites; Cell Line, Tumor; Combinatorial Chemistry Techniques; Crystallography, X-Ray; Drug Design; ErbB Receptors; Humans; Kinetics; Models, Molecular; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship; Substrate Specificity; Vascular Endothelial Growth Factor Receptor-2

2008